Expression and significance of vascular endothelial growth factor A and C in leukemia central nervous system metastasis

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 359-366

  Tang, Yue Ting ^a   Jiang, Fang ^a   Guo, Li ^a   Si, Meng Ya ^a   Jiao, Xiao Yang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Central nervous system leukemia; Cerebrospinal fluid; VEGF A; VEGF C

Indexed keywords

ALBUMIN; CYTARABINE; DOXORUBICIN; IDARUBICIN; RETINOIC ACID; VASCULOTROPIN A; VASCULOTROPIN C;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; BLOOD LEVEL; CANCER PROGNOSIS; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM LEUKEMIA; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; HUMAN; LEUKEMOGENESIS; LUMBAR PUNCTURE; MALE; METASTASIS FREE SURVIVAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADOLESCENT; ADULT; BLOOD-BRAIN BARRIER; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; YOUNG ADULT;

EID: 84875379598     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.10.008     Document Type: Article

References (61)

1. Jabbour E., Thomas D., Cortes J., Kantarjian H.M., O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 2010, 116(10):2290-2300.
2. Gibson L.F. Survival of B lineage leukemic cells: signals from the bone marrow microenvironment. Leuk Lymphoma 2002, 43(1):19-27.
3. Ransohoff R.M., Kivisakk P., Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003, 3(7):569-581.
4. Li K.A., Zhang R.M., Zhang F., Zhao J.L., Li Y.J., Wang X.F., et al. Studies of pathology and VEGF expression in rabbit cerebrospinal fluid metastasis: application of dynamic contrast-enhanced MRI. Magn Reson Imaging 2011, 29(8):1101-1109.
5. Feng S., Huang Y., Chen Z. Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia?. Med Hypotheses 2011, 76(5):618-621.
6. Akers S.M., Rellick S.L., Fortney J.E., Gibson L.F. Cellular elements of the subarachnoid space promote ALL survival during chemotherapy. Leuk Res 2011, 35(6):705-711.
7. Engelhardt B., Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009, 31(4):497-511.
8. Arshad F., Wang L., Sy C., Avraham S., Avraham H.K. Blood-brain barrier integrity and breast cancer metastasis to the brain. Pathol Res Int 2010, 2011:920509.
9. Fiedler W., Staib P., Kuse R., Duhrsen U., Flasshove M., Cavalli F., et al. Role of angiogenesis inhibitors in acute myeloid leukemia. Cancer J 2001, 7(Suppl. 3):S129-S133.
10. Su J.L., Yen C.J., Chen P.S., Chuang S.E., Hong C.C., Kuo I.H., et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007, 96(4):541-545.
11. Bellamy W.T., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59(3):728-733.
12. Fielder W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M., et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 1997, 11(8):1234-1237.
13. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18(1):4-25.
14. Broers A.E., van Der Holt R., van Esser J.W., Gratama J.W., Henzen-Logmans S., Kuenen-Boumeester V., et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000, 95(7):2240-2245.
15. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96(6):2240-2245.
16. Zhu Z., Hattori K., Zhang H., Jimenez X., Ludwig D.L., Dias S., et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003, 17(3):604-611.
17. Dias S., Choy M., Alitalo K., Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002, 99(6):2179-2184.
18. de Jonge H.J., Valk P.J., Veeger N.J., ter Elst A., den Boer M.L., Cloos J., et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 116(10):1747-1754.
19. Bates D.O., Hillman N.J., Williams B., Neal C.R., Pocock T.M. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002, 200(6):581-597.
20. Chi O.Z., Hunter C., Liu X., Weiss H.R. Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia. Exp Neurol 2007, 204(1):283-287.
21. Argaw A.T., Gurfein B.T., Zhang Y., Zameer A., John G.R. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 2009, 106(6):1977-1982.
22. Croll S.D., Ransohoff R.M., Cai N., Zhang Q., Martin F.J., Wei T., et al. VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp Neurol 2004, 187(2):388-402.
23. Tham E., Gielen A.W., Khademi M., Martin C., Piehl F. Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand J Immunol 2006, 64(6):609-622.
24. Coenjaerts F.E., van der Flier M., Mwinzi P.N., Brouwer A.E., Scharringa J., Chaka W.S., et al. Intrathecal production and secretion of vascular endothelial growth factor during cryptococcal meningitis. J Infect Dis 2004, 190(7):1310-1317.
25. Sampath P., Weaver C.E., Sungarian A., Cortez S., Alderson L., Stopa E.G. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control 2004, 11(3):174-180.
26. Stockhammer G., Poewe W., Burgstaller S., Deisenhammer F., Muigg A., Kiechl S., et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000, 54(8):1670-1676.
27. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103(4):620-625.
28. Harms D.O., Janka-Schaub G.E. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000, 14(12):2234-2239.
29. Mastrangelo R., Poplack D., Bleyer A., Riccardi R., Sather H., D'Angio G. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol 1986, 14(3):191-194.
30. Hirohata S., Isshi K., Oguchi H., Ohse T., Haraoka H., Takeuchi A., et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997, 82(1):12-17.
31. Andersson L.M., Hagberg L., Fuchs D., Svennerholm B., Gisslen M. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals-correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 2001, 7(6):542-547.
32. van der Flier M., Stockhammer G., Vonk G.J., Nikkels P.G., van Diemen-Steenvoorde R.A., van der Vlist G.J., et al. Vascular endothelial growth factor in bacterial meningitis: detection in cerebrospinal fluid and localization in postmortem brain. J Infect Dis 2001, 183(1):149-153.
33. Kut C., Mac Gabhann F., Popel A.S. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007, 97(7):978-985.
34. Takano S., Yoshii Y., Kondo S., Suzuki H., Maruno T., Shirai S., et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996, 56(9):2185-2190.
35. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7(1):41-53.
36. Pottiez G., Flahaut C., Cecchelli R., Karamanos Y. Understanding the blood-brain barrier using gene and protein expression profiling technologies. Brain Res Rev 2009, 62(1):83-98.
37. Wang W., Dentler W.L., Borchardt R.T. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 2001, 280(1):H434-H440.
38. Petty M.A., Lo E.H. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 2002, 68(5):311-323.
39. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006, 8(11):1223-1234.
40. Davis B., Tang J., Zhang L., Mu D., Jiang X., Biran V., et al. Role of vasodilator stimulated phosphoprotein in VEGF induced blood-brain barrier permeability in endothelial cell monolayers. Int J Dev Neurosci 2010, 28(6):423-428.
41. Chamberlain M.C., Glantz M., Groves M.D., Wilson W.H. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009, 36(4 (Suppl. 2)):S35-S45.
42. Wu J.M., Georgy M.F., Burroughs F.H., Weir E.G., Rosenthal D.L., Ali S.Z. Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone?. Diagn Cytopathol 2009, 37(11):820-824.
43. Vanel D. Editorial: imaging of a bone tumor: easy to use news. Eur J Radiol 2011, 77(1):2.
44. Hegde U., Filie A., Little R.F., Janik J.E., Grant N., Steinberg S.M., et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005, 105(2):496-502.
45. Kawashima K., Nagura E., Yamada K., Hamajima N. Leukemia relapse in long-term survivors of acute leukemia. Cancer 1985, 56(1):88-94.
46. Sirvent N., Suciu S., Rialland X., Millot F., Benoit Y., Plantaz D., et al. Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. Eur J Cancer 2011, 47(2):239-247.
47. Groves M.D., Hess K.R., Puduvalli V.K., Colman H., Conrad C.A., Gilbert M.R., et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009, 94(2):229-234.
48. Gisterek I., Matkowski R., Lacko A., Sedlaczek P., Szewczyk K., Biecek P., et al. Serum vascular endothelial growth factors A, C and D in human breast tumors. Pathol Oncol Res 2010, 16(3):337-344.
49. Li W.W., Hutnik M., Gehr G. Antiangiogenesis in haematological malignancies. Br J Haematol 2008, 143(5):622-631.
50. Loges S., Heil G., Bruweleit M., Schoder V., Butzal M., Fischer U., et al. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005, 23(6):1109-1117.
51. Hou Y., Shin Y.J., Han E.J., Choi J.S., Park J.M., Cha J.H., et al. Distribution of vascular endothelial growth factor receptor-3/Flt4 mRNA in adult rat central nervous system. J Chem Neuroanat 2011, 42(1):56-64.
52. Law A., Karp D.D., Dipetrillo T., Daly B.T. Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer 2001, 92(1):160-164.
53. Laningham F.H., Kun L.E., Reddick W.E., Ogg R.J., Morris E.B., Pui C.H. Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology 2007, 49(11):873-888.
54. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009, 29(6):789-791.
55. Zhou Z., Reddy K., Guan H., Kleinerman E.S. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res 2007, 5(11):1125-1132.
56. Biselli-Chicote P.M., Oliveira A.R., Pavarino E.C., Goloni-Bertollo E.M. VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. J Cancer Res Clin Oncol 2012, 138(3):363-370.
57. Ruiz de Almodovar C., Lambrechts D., Mazzone M., Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 2009, 89(2):607-648.
58. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23(7):879-894.
59. Fernandis A.Z., Prasad A., Band H., Klosel R., Ganju R.K. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004, 23(1):157-167.
60. Feng S., Cen J., Huang Y., Shen H., Yao L., Wang Y., et al. Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS ONE 2011, 6(8):e20599.
61. Kryczek I., Lange A., Mottram P., Alvarez X., Cheng P., Hogan M., et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005, 65(2):465-472.